Research Peptides in 2026: How the FDA and EMA Treat Them
A neutral 2026 map of how the FDA, the EMA and the anti-doping world actually treat research peptides — and why “Research Use Only” is a defined legal frame, not a loophole.
-
-
The EMA’s First Synthetic-Peptide Guideline, Explained for European Researchers
On 1 June 2026 the European Medicines Agency published its first rulebook for manufacturing synthetic-peptide medicines. Here is what it actually says, what it does not touch, and why it quietly raises the quality bar for everyone.
-
The FDA’s July 2026 Peptide Review, Explained
A US advisory committee meets on 23–24 July 2026 to weigh whether a group of research peptides — including BPC-157 and TB-500 — should return to a category permitting regulated compounding. Here is what is actually being decided, and what it does not change.
